EyePoint, Inc.

EYPT

Held by 2 specialist biotech funds

Share on X

Fund Holdings

OrbiMed Advisors Rock Springs Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management4.7%Feb 14, 2025

SC 13G/ARA Capital Management6.1%Feb 14, 2024

SC 13G/A

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 2,468,314Value: $45.1M

# Signal Note: OrbiMed Initiates $45.1M Position in EyePoint OrbiMed's new 2.5M share stake signals conviction in EyePoint's sustained-release ocular portfolio, likely anchored on YUTIQ (fluocinolone acetonide implant) for non-infectious uveitis, which generated ~$37M in 2023 revenue with demonstrated label expansion potential. The timing suggests confidence in near-term catalysts, potentially including further geographic expansion, additional indication approvals, or improved reimbursement trajectory for the company's depot-based delivery platform.

Rock Springs CapitalNEW

More EYPT Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

MLYS2 funds NBIX2 funds APLS2 funds FOLD2 funds BCAX2 funds ARGX2 funds OCUL2 funds JANX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Rock Springs Capital Initiates EyePoint Position** Rock Springs' $4.7M entry into EYPT likely reflects conviction in the company's ophthalmology pipeline, particularly YUTIQ (fluocinolone acetonide implant) for non-infectious uveitis, which achieved FDA approval in October 2021 and is ramping commercialization. The timing suggests confidence in near-term revenue inflection and potential label expansions or additional indications under development. As a concentrated healthcare specialist, Rock Springs' initiation signals they see catalysts outweighing current valuation risks.